Roche ranked as one of the top three most sustainable healthcare companies in the Dow Jones Sustainability Indices for the thirteenth year running
- The ranking acknowledges Roche’s commitment to sustainability as an integral part of its business strategy
- Roche performed particularly well in Operational Eco-Efficiency, Environmental and Social Reporting
Basel, 15 November 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) has again been recognised as one of the most sustainable companies in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance. The DJSI family of indices serves as a benchmark for investors who integrate sustainability considerations into their portfolios.
Roche has maintained its leadership through its sustainability strategy, which is fully embedded in the company’s business and culture.
“We are proud of being recognised once again for our consistent and lasting engagement on sustainability,” says Roche CEO Severin Schwan. “This achievement strongly resonates in the context of our 125-year anniversary, and highlights our heritage and our continued commitment to society.”
Sustainability at Roche
For 125 years, sustainability has been an integral part of Roche’s business. Roche follows a holistic approach when managing sustainability: In addition to improving access to products, the company’s strategy also focuses on achieving continuous progress in areas such as social responsibility, environmental protection, supply chain sustainability, people attraction and retention.
Roche makes its biggest contribution to society by improving healthcare provision. It does so by developing the best diagnostic tests and medicines capable of meeting some of the world’s most pressing medical needs.
Roche is aware that this cannot be done alone. The company knows that the key to creating sustainable value and growth lies in partnering with stakeholders and engaging in open, constructive dialogue. By doing so, Roche generates value for society and achieves sustainable economic growth for the company.
Examples of our activities in sustainability areas can be found here:
About the Dow Jones Sustainability Indices (DJSI)
This global ranking is published annually by the S&P Dow Jones Indices and SAM and measures the performance of the world’s sustainability leaders. SAM invites publicly traded companies to participate. Companies are selected for the indices according to a systematic Corporate Sustainability Assessment (CSA) performed by SAM. Only firms that lead their industries based on this assessment are included in the indices. This is determined by a comprehensive assessment of long-term economic, environmental and social criteria that take account of general as well as industry-specific sustainability trends.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, the company has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the thirteenth consecutive year, Roche has been recognised as one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
|Roche Investor Relations|
| Dr. Karl Mahler|
Phone: +41 61 68-78503
| Jon Kaspar Bayard|
Phone: +41 61 68-83894
| Dr. Sabine Borngräber|
Phone: +41 61 68-88027
| Dr. Bruno Eschli|
Phone: +41 61 68-75284
| Dr. Birgit Masjost|
Phone: +41 61 68-84814
| Dr. Gerard Tobin|
Phone: +41 61 68-72942
|Investor Relations North America|
| Loren Kalm|
Phone: +1 650 225 3217